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Abstract
Background: The burden of cardiovascular disease is rising in sub-Saharan Africa with hypertension being the main
risk factor. However, context-specific evidence on effective interventions for primary prevention of cardiovascular
diseases in resource-poor settings is limited. This study aims to evaluate the feasibility and cost-effectiveness of one
such intervention—the “Sustainable model for cardiovascular health by adjusting lifestyle and treatment with
economic perspective in settings of urban poverty”.
Methods/Design: Design: A prospective quasi-experimental community-based intervention study.
Setting: Two slum settlements (Korogocho and Viwandani) in Nairobi, Kenya.
Study population: Adults aged 35 years and above in the two communities.
Intervention: The intervention community (Korogocho) will be exposed to an intervention package for primary
prevention of cardiovascular disease that comprises awareness campaigns, household screening for cardiovascular
diseases risk factors, and referral and treatment of people with high cardiovascular diseases risk at a primary health
clinic. The control community (Viwandani) will continue accessing the usual standard of care for primary prevention
of cardiovascular diseases in Kenya.
Data: Demographic and socioeconomic data; anthropometric and clinical measurements including blood pressure.
Population-based data will be collected at the baseline and endline—12 months after implementing the intervention.
These data will be collected from a random sample of 1,610 adults aged 35 years and above in the intervention and
control sites at both baseline and endline. Additionally, operational (including cost) and clinic-based data will be
collected on an ongoing basis.
Main outcomes: (1) A positive difference in the change in the proportion of the intervention versus control study
populations that are at moderate or high risk of cardiovascular disease; (2) a difference in the change in mean systolic
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blood pressure in the intervention versus control study populations; (3) the net cost of the complete intervention
package per disability-adjusted life year gained.
Analysis: Primary outcomes comparing pre- and post-, and operational data will be analyzed descriptively and “impact”
of the intervention will be calculated using double-difference methods. We will also conduct a cost-effectiveness
analysis of the intervention using World Health Organization guidelines.
Discussion: The outcomes of the study will be disseminated to local policy makers and health planners.
Trial registration: Current controlled trials ISRCTN84424579
Keywords: Prevention, Cardiovascular risk factors, Cost-effectiveness, Slums, Sub-Saharan Africa
Background
The burden of cardiovascular diseases (CVD) is rising in
sub-Saharan Africa (SSA) where up to 12.5% of deaths
are attributable to CVD (SSA) [1,2]. Hypertension is the
leading risk factor for CVD worldwide, and it is be-
coming even more pronounced in SSA [3]. For ex-
ample, the average blood pressure of people in Kenya
has risen from approximately 125 mmHg in 1990 to
around 130 mmHg in 2010 [4]. This is in contrast to
countries in North America and Western Europe where
the weighted average blood pressure has decreased by
approximately 3 mmHg in the same period [5]. This
is partly because countries in SSA are mostly in an
earlier phase of the epidemiological transition [6,7] in
which relatively low levels of behavioral CVD risk fac-
tors are increasing rapidly compared to their counterparts
elsewhere in the world [8,9]. On the other hand, countries
in SSA also score relatively poorly in terms of availability
of and access to medication for treating CVD and their
risk factors [10].
Moreover, the health and economic impact of CVD
in SSA and other low-resource settings is dispropor-
tionately higher than elsewhere [11]. Not only do people
in SSA who suffer from CVD have a higher chance of
disability or death, they are also more likely to have
developed CVD earlier in life—during their most eco-
nomically productive years [12,13]. At the same time,
most countries in SSA are still struggling with a high bur-
den of infectious diseases such as malaria and HIV/AIDS.
The so-called risk of a “double burden of disease” due
to infectious and non-communicable diseases poses a
serious threat to the weak health systems in such
resource-poor settings [14]. Hence, there is an urgent
need to implement and evaluate cost-effective inter-
ventions for primary prevention of CVD in such set-
tings. Generally, primary prevention of CVD could
involve lifestyle interventions targeting the common
behavioral risk factors for CVD—tobacco use, alcohol
misuse, unhealthy diet and lack of adequate physical
activity [15]. Other primary prevention strategies tar-
get the physiological risk factors for CVD including
drug therapy for the treatment and control of high
blood pressure, glucose and cholesterol [15]. While
there is strong evidence of the benefits of lifestyle
modification efforts in individuals at ‘high risk’, the
evidence of such interventions when implemented at
a population level (including those at ‘low risk’) is
less convincing [16].
Modeling studies have estimated that scaling up the
coverage of appropriate drug therapy will be very cost-
effective in reducing the burden of CVD in low-resource
settings [17]. Specifically, it appears that improving avail-
ability of appropriate medication for people with hyper-
tension may play a crucial role in slowing down the
rising trends of CVD mortality in SSA [18]. However, in
order to be successful, the scaling up of antihypertensive
medication and indeed other cost-effective interventions
for primary prevention of CVD needs to overcome cer-
tain barriers at both the population and individual levels.
First, the level of awareness about hypertension and
other CVD risk factors is low, and in most countries in
SSA screening opportunities at the population level are
limited [7,19,20]. At the individual level, access to quality
treatment and follow-up care for hypertension and CVD
in general remains poor [21,22]. Primary health care
facilities in SSA often lack essential medicines and tech-
nologies for diagnoses and treatment of hypertension
and other CVD risk factors [23]. In addition, standard
treatment guidelines or protocols for CVD are usually
lacking and/or not implemented [24].
Therefore, health systems in most countries in SSA
might not be prepared to deal with a hypertension or
CVD epidemic even though cost-effective interventions
are available. This is more so among the urban poor
who are resident in vast slums across the sub-continent.
There is a paucity of information on CVD and its risk
factors in slums in SSA. Yet, more than 60 percent of
urban populations in the sub-continent reside in slums
or informal settlements [25]. For instance, in Nairobi
(Kenya), up to 70 percent of the urban population re-
sides in vast slums across the city [26]. These slums are
typically underserved by social amenities including ac-
cess to quality health care. Some evidence suggests that
such populations fare worse than their non-slum and
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even rural counterparts on most health measures includ-
ing high prevalence of CVD and low levels of awareness,
treatment and control of hypertension [27].
The “Sustainable model for Cardio-vascular health
by Adjusting Lifestyle and treatment with Economic
perspective in settings of Urban Poverty” (acronym:
SCALE UP) study is designed to implement a com-
prehensive intervention package of primary prevention
strategies for CVD risk reduction in a slum setting in
Nairobi, Kenya, and to evaluate its feasibility and cost-
effectiveness. Specifically, the intervention package inte-
grates approaches that aim to raise awareness and
improve detection of hypertension at the population
level. Additionally, the intervention aims to provide access
to standardized quality treatment and follow-up for hyper-
tensive patients with the overall objective of reducing their
CVD risk profile in such a low-resource setting.
Methods/Design
Design
SCALE UP is a community-based intervention aimed at
reducing cardiovascular risk in people free from cardio-
vascular disease. It is designed to allow for a before-after
comparison of cardiovascular risk between a control and
an intervention setting.
Setting
Since 2002, the African Population and Health Research
Center (APHRC) has been operating the Nairobi Urban
Health Demographic Surveillance System (NUHDSS).
Details about the NUHDSS have been provided else-
where [28]. In brief, the Demographic Surveillance Area
(DSA) covers two socio-demographically similar slums
(Korogocho and Viwandani), each located about 5 to
10 km from Nairobi (Kenya). There are approximately
72,000 individuals resident in 25,000 households almost
equally distributed in both slums. High levels of poverty,
unemployment and lack of social amenities, including lim-
ited access to quality primary health care, characterize
both slums. Specifically, there are only two public primary
health facilities located on the outskirts of either slum.
However, there are numerous private health providers in
the slums, the majority of which are unlicensed and un-
regulated. Most of the private facilities operate largely for
profit and rarely provide professional quality care. How-
ever, slum residents seem to prefer these services to the
public ones for a number of reasons, including easier ac-
cess, more approachable staff and flexible working hours
(APHRC unpublished observations).
Intervention community
Korogocho slum, which has eight villages, each with
between 3,000–5,000 residents, will be the interven-
tion site. This slum has one centrally located private
health facility with a reliable track record of providing
primary health services. This facility is known as Provide
International Clinic. It is well known in the slum and,
although most patients still make out-of-pocket pay-
ments for services received, the clinic offers non-
profit services at highly subsidized (through donor
funding) costs to residents. There are no physicians
or medical officers present at this clinic. Nurses and
clinical officers (health personnel with a diploma in
clinical medicine) provide consultations. However, the
facility does not typically provide primary preventive
services for CVD such as screening and treatment of
hypertension. The location of this clinic and the ab-
sence of primary preventive services for CVD guided
our choice of intervention site.
Control community
Viwandani slum will be the control site. There are seven
villages in Viwandani with approximately 2,000–4,000
residents each. Unlike Korogocho, Viwandani does not
have a centrally located health facility. The main health
facility serving Viwandani is located on the outskirts of
the slum. This facility is publicly owned and represents
the usual standard of care for CVD that is available to
underserved slum communities in Nairobi, thus making
Viwandani the appropriate ‘control’ site in comparison
with Korogocho. The clinic in Viwandani operates a
weekly CVD clinic where approximately 30 patients
with uncomplicated hypertension and/or diabetes from
Viwandani slums are seen on each clinic day. Like the
facility in Korogocho, the Viwandani clinic is also run by
nurses and clinical officers.
Study population
Inclusion criteria
Adults aged 35 years and above living in the slums of
Korogocho and Viwandani who give informed consent
to participate in the study. The main reason for this age
cutoff is because the group above 35 years represents
21% of the total population and accounts for 71% of all
known hypertensive cases, according to a CVD risk
factor survey conducted in the DSA in 2008 (APHRC
unpublished data). Also, due to financial constraints,
the study could not be extended to an unrestricted
age group. Persons with diagnosed hypertension and/
or on antihypertensive therapy will be included in the
study.
Exclusion criteria
The following will be excluded from the study: pregnant
women, persons with self-reported pre-existing CVD
(myocardial infarction, stroke, heart failure and angina)
and all those unable to provide informed consent such
as the mentally incapacitated.
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The intervention package
APHRC and the Amsterdam Institute for Global Health
and Development (AIGHD) have developed an interven-
tion package for primary prevention of CVD in urban
slums based on findings from earlier studies by APHRC
on CVD risk factors in this specific setting [29], litera-
ture review [30] and input from various experts and
local stakeholders. The intervention package is com-
posed of four components, which will be described below
(see Figure 1).
(1) Raising awareness and (2) improving access to
screening
The first two components of the intervention package
include door-to-door household visits by community
health workers (CHWs) to raise awareness about CVD
risk and to conduct screening of each eligible adult aged
35 years and above in the intervention slum in order to
determine their individual CVD risk profile. CHWs are
typically community-based volunteers who have an
interest in community health. They are usually well
known by the community and most have received some
form of basic training in community health activities
such as peer health education for HIV/AIDS prevention.
The SCALE UP study will recruit CHWs to represent
each of the eight villages in the intervention slum. These
CHWs will then be trained and equipped to perform the
door-to-door visits and screening exercise in their
respective villages in the intervention slum.
Two weeks prior to the commencement of the screen-
ing exercise, there will be public awareness campaigns
organized by the CHWs in each village of the interven-
tion slum. This awareness campaigns will take place at
community gatherings (known locally as barazaas). At
these barazaas, CHWs together with village leaders will
inform the audience about the burden of CVD in the
community and the need to participate in the door-
to-door screening. Additionally, CHWs will visit religious
gatherings, usually held at local churches and mosques,
to provide the same information. Such gatherings are
usually well attended by respected members of the com-
munity who will then pass the information on to others.
Finally, radio jingles announcing the door-to-door
screening will be aired daily on the local radio station
(Korogocho FM) over a 2-week period from the start of
the intervention.
The SCALE UP study investigators will train the
CHWs to assess the study participants’ level of engage-
ment in risky lifestyle behavior including tobacco use,
alcohol misuse, physical activity levels and dietary
habits. CHWs will also be trained in performing basic
anthropometric and clinical measurements including
height, weight, waist and hip circumference, blood pres-
sure and blood glucose. They will be provided with the
appropriate equipment for the clinical measurements
(see Table 1). Also, each CHW will be trained to pro-
vide brief counselling assistance (BCA) of healthy life-
style modification using the six As approach –Ask,
Advice, Assist, Arrange, Agree and Affirm [31]. Trad-
itional BCA does not include the sixth A (Affirm) as
a separate entity. However, the SCALE UP team has in-
cluded this component to emphasize the need for CHWs
to encourage study participants to continue with any
healthy lifestyle behavior in which they reported being
currently engaged. All eligible and consenting study par-
ticipants will receive BCA during the door-to-door visit. If
the eligible adult(s) are not at home, the CHWs will try to
visit another time, with a maximum of two attempts.
Figure 1 Overview of interventions in the SCALE UP intervention package. 1CHW: Community health worker.
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(3) Facilitating access to quality treatment
The third component of the intervention package in-
cludes facilitating access to quality treatment for hyper-
tension. During the door-to-door screening all persons
with elevated blood pressure (≥140 mmHg systolic and/
or ≥90 mmHg diastolic) will be referred to the interven-
tion clinic—Provide International Clinic—by the CHWs.
A project supervisor will independently visit each person
referred by a CHW to perform a confirmatory blood
pressure check before that person proceeds to the inter-
vention clinic. Those people below 35 years who are in-
terested in knowing about their blood pressure and/or
CVD risk will be referred to a central screening point in
the slum. The results of this additional screening will
not be considered as part of this study.
Based on previous experience in the slums, the SCALE
UP team included two incentives in the intervention
package to encourage referred study participants to seek
care at the intervention clinic. First, each referred par-
ticipant will receive a voucher for a first free consult-
ation at the clinic. At the same time, CHWs will receive
a cash reward of approximately 3 US dollars (US$ 3.00)
for each of their referred participants who attends the
clinic for the first time. Hopefully, this cash reward will
be a reasonable incentive for each CHW to follow up
those whom they have referred and encourage them per-
sonally to attend the clinic for the first time.
In addition to improving access to treatment, it is also
important to ensure that the treatment is of high quality.
Thus, as part of the intervention package, the SCALE
UP team will build the capacity of the intervention
clinic to provide primary care services for CVD risk
management. To this end, the intervention clinic will be
equipped with basic and essential diagnostic equipment
for CVD including a validated digital blood pressure
measurement device, measurement tape, weighing scale,
height measurement board, glucometer and blood glucose
test strips. These devices have been selected in accord-
ance with WHO essential technologies and tools for
implementing non-communicable disease (NCD) inter-
ventions in primary health care using non-physician health
workers [32].
Selected non-physician health workers including clin-
ical officers and nurses from the intervention clinic will
be trained on how to implement a standard protocol for
management of hypertension at the primary health care
level in low-resource settings. This protocol was devel-
oped by the SCALE UP study team in collaboration with
senior cardiologists with experience in primary care
from the University of Nairobi and the Division of Non-
Communicable Diseases in the Kenya Ministry of Health
(see Additional file 1). The various treatment thresholds
for hypertension given in the protocol are based on a
non-laboratory-based CVD risk prediction assessment
method [33]. Using this method, all participants with
high blood pressure who enroll at the intervention clinic
will be classified as low (≤10%), moderate (>10-20%) or
high (>20%) risk based on their individual 10-year CVD
risk (fatal and non-fatal) profile. Treatment for hyperten-
sion will range from lifestyle modification to use of lo-
cally available antihypertensive medication depending on
the risk profile of the participants. The treatment thresh-
old and target blood pressure are specified in Additional
file 1.
In addition to referring participants with high blood
pressure to the intervention clinic, CHWs will also be
instructed to refer other potentially moderate to high
CVD risk study participants. Specifically, CHWS will be
instructed to perform random blood glucose tests on all
study participants who are older than 55 years of age
AND have any of the following: systolic blood pressure
≥140 mmHg, diastolic blood pressure ≥90 mmHg OR
abnormal waist circumference (>102 cm for men and
>88 cm for women). Participants whose random blood
glucose is ≥11.1 mmol/l will be referred to the interven-
tion clinic for follow-up. At the clinic, random blood
glucose will be repeated, and if still ≥11.1 mmol/l, the
participant will be managed in accordance with the
Kenya national clinical guidelines for management of
diabetes mellitus [34]. As diabetes management is not a
primary objective of the SCALE UP study, the intervention
clinic will only be stocked with metformin—a relatively
affordable oral hypoglycemic medication. Participants re-
quiring other antidiabetic medication including insulin,
based on the national guidelines, will be referred to the
nearest district hospital.
(4) Promoting long-term adherence
The final component of the intervention package aims
to promote long-term adherence among participants
enrolled in the intervention clinic. For logistic rea-
sons, all participants at the intervention clinic will be
required to visit the clinic at least once every month
for the entire duration of the study. Based on previ-
ous experience in the study area, longer follow-up pe-
riods tend to increase the chances of patient loss to
follow-up. Beyond the regular follow-up interval, the
adherence component of the intervention package will
also include two subcomponents:
Table 1 List of screening equipment
Equipment Units
SECA 201 circumference measurement tape cm
SECA 874 flat scale electronic kg
SECA 214 stadiometer transportable cm
OMRON M6 blood pressure machine mmHg
ACCUCHECK glucometer and test strips mmol/l
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First, there will be an incentive-driven support group
system for all participants enrolled into the intervention
clinic. Each support group will have about 10–30 mem-
bers drawn from participants living within the same vil-
lages. CHWs from respective villages will coordinate the
activities of the support groups. This subcomponent of
the intervention package seeks to leverage on the group
dynamics of these support groups to promote adherence
among participants. To this end, there will be a group
incentive that rewards the entire group for achieving a col-
lective level of adherence to clinic appointments at a level
of 80% or more for a consecutive period of 6 months. If
achieved, the entire group will receive a rebate in the
monthly cost of their medication equivalent to approxi-
mately one-third of the usual cost. The estimated usual
cost of medication for hypertension in the intervention
clinic is Ksh 150 (US$ 1.8) per month. Additionally, the
CHW will also receive a cash incentive to follow up every
individual participant in the support group and encourage
him/her to adhere to the clinic appointments. If partici-
pants remain adherent over the first 6 months of clinic
enrollment, the CHW will receive a cash bonus of ap-
proximately US$ 1.8 per participant. Such an incentive is
crucial because a previous study in the study areas found
that almost 70% of hypertensive patients who drop out of
primary health care clinics do so within the first 6 months
(APHRC unpublished observations). The use of incentives
to improve patient adherence has been tested in other
settings, though the evidence is mixed [35].
There are other expected benefits that participants will
enjoy for being part of the support group. The support
group will hopefully be a forum where participants can
share in the experiences of living with hypertension and
learn from each other on how best to cope with this
condition. Also, highly motivated participants will be
selected by CHWs to become peer-educators. There will
be train-the-trainer sessions where these participants
will be trained by local experts on how to adopt healthy
lifestyle changes such as healthy cooking classes and
physical activity sessions, to mention a few.
The second subcomponent of the intervention package
aimed at promoting long-term adherence is the use of
the mobile phone Short Message Service (SMS). Unpub-
lished data from the study area show that more than
80% of the adult population reports owning a mobile
phone, and the remainder report having a close neighbor
or other family member who owns a mobile phone
through which they can be reached. Studies from other
chronic conditions such as HIV have shown encouraging
levels of success in the use of SMS to improve adherence
[36]. In the SCALE UP study, an SMS will be sent every
week to remind participants about their next clinic
appointments, to take their medication and to provide
them with healthy lifestyle tips.
Data management
To measure the health effect of the whole intervention
package at the population level, there will be two cross-
sectional surveys (before and after, 12 months apart).
Data will be collected on demographic and socioeco-
nomic variables, behavioral risk factors such as tobacco
and alcohol use, anthropometric measurements such as
height and weight, and clinical measurements such as
blood pressure and random blood glucose. Four cadres
of field staff will be involved in data collection. These
include field interviewers, CHWs, field assistants and
supervisors.
Field interviewers will be trained by the SCALE UP
study investigators to collect the demographic, socioeco-
nomic and behavioral risk factor data using structured
interviews during the cross-sectional surveys in both the
intervention and control sites. In the intervention site,
the anthropometric and clinical measurement will be
performed by CHWs. In the control site, however, mea-
surements will be performed by trained field assistants
rather than CHWs. This is because CHWs are consid-
ered to be part of the intervention. Each interview is es-
timated to last approximately 30 min, followed by the
physical and clinical measurements. The field staff will
be instructed to follow standard procedures for all mea-
surements as outlined in the WHO STEPS manual [37].
Specifically, while taking the blood pressure, field staff
will be required to ensure that the respondent remains
seated for about 5 min, with no talking, holding the
monitoring device on the upper arm and holding it at
heart level against his/her chest. The blood pressure will
be measured three times, using the left arm. To minimize
observer bias, validated digital equipment will be used,
the OMRON M6® (Digital Automatic Blood Pressure
Monitor). Note that referral of participants for further
management will be based on the average of the three
blood pressure measurements (systolic ≥140 and/or
diastolic ≥90 mmHg).
At the intervention clinic, additional information will
be collected on clinic attendees to monitor their pro-
gress and evaluate the effect of the intervention on
blood pressure control and overall CVD risk profile.
Baseline interviews will be conducted with each clinic
attendee by trained field interviewers. Immediately after
an interview, nurses at the clinic will record physical and
clinical measurements for each clinic attendee. These
measurements will be repeated each time the participant
attends the intervention clinic over a period of at least
12 months. At the end of this period, an endline inter-
view will be conducted with each clinic attendee. Table 2
summarizes the data to be collected over the interven-
tion period.
All data will be entered onto electronic data collection
forms pre-loaded into Mecer® Netbooks and stored in an
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SQL database managed by the data unit of APHRC. To
ensure data quality, the field staff will be trained in inter-
viewing techniques and how to use the Netbooks. Data
collection forms will be translated into Swahili and back
to English for consistency. Interviews will be conducted
in Swahili—the main lingua franca in the study areas.
Supervisors will be recruited to conduct spot checks of
at least 5% of randomly selected interviews conducted
by each field staff they supervise. They will also perform
a random check of 5% of data collection forms com-
pleted by field staff. Forms will be checked for errors,
missing information and inconsistent responses, and,
where necessary, field staff will be required to revisit a
study participant in order to clarify any erroneous
information.
At the intervention clinic, qualified data entry clerks
will be trained to double-capture all clinic data collected
by the nurses and clinical officers during the patient
consult. Clinic data will also be electronically captured
using Netbooks.
Finally, cost data will be collected on an on-going basis
in order to feed into the cost-effectiveness analysis of
the intervention package. This will be done through an
adapted checklist to collect information on costs and re-
lated time spent in all aspects of implementing the inter-
vention package.
Primary outcomes
The primary outcomes of the SCALE UP study are:
1. The difference in change in the proportion of the
study populations (intervention and control slums)
that are at high risk of CVD (defined as >10% risk of
developing cardiovascular event in the next 5 years
based on the method for assessment of
cardiovascular disease risk by Gaziano et al. [33]).
2. The difference in change in mean systolic blood
pressure in the study populations (intervention and
control slums).
3. The change in mean systolic blood pressure among
participants attending the local clinic (intervention
slum only).
4. The net cost of the intervention package per
disability-adjusted life year gained (intervention slum
only).
Secondary outcomes
1. Prevalence of hypertension in the intervention and
control slums.
2. Proportion of hypertensive respondents who are on
treatment, and under control, in the intervention
and control slums.
3. Proportion of high-risk participants who sought first
time treatment after screening and referral.
4. Prevalence of behavioral and biological CVD risk
factors: smoking, physical exercise, diet, alcohol
intake, body mass index, waist circumference and
waist-to-hip ratio in the intervention and control
slums.
Sample size considerations
In order to detect a 5% reduction at endline in the pro-
portion of adults aged 35 years and above who are at
moderate or high risk of CVD [38,39] in the intervention
population versus no change in the control population
(assuming both populations have similar start prevalence
at 25%), we need 2,927 respondents in both intervention
and control sites, using an alpha of 0.05 and power
(1-beta) of 0.90. Taking into account a non-response
rate of 10%, we will approach 3,220 individuals per
cross-sectional study—that is, 1,610 per site at base-
line and endline surveys, respectively.
The sampling frame will be based on the most recently
updated NUHDSS database. This database contains
details of about 72,000 individuals including names, lo-
cations, gender, dates of birth and residential status in
both slums. In the control site, we will use computer
randomization (STATA® statistical software) to select the
1,610 individuals aged 35 years and older per site for
each cross-sectional survey.
In the intervention site, the same computer randomization
process will be followed. However, unlike the control site,
the 1,610 individuals to be included in the cross-sectional
survey analysis will be collected retrospectively. In other
words, the intervention package will be delivered to all
Table 2 Data collection schedule
Data Baseline Ongoing Endline
Population based X X
Socio-demographic characteristics X
CVD behavioral risk factors X X
Physical measurements
(weight, height, waist and hip
circumference, blood pressure)
X X
Blood testing (glucose) X X
Clinic based
Physical measurements
(weight, height, waist and hip
circumference, blood pressure)
X X X
Lifestyle modification advice X
Drug prescriptions and side effects X
Morisky adherence score X
Operational data
Costs X
Timesheets X
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adults aged 35 years or older in the intervention site—that
is, 6,780 individuals according to the DSS database (as at
15 June 2012).
At the clinic level, we calculated that in order to detect
a 10 mmHg reduction in blood pressure (at 20 mmHg
standard deviation, alpha of 0.05 and 1-β on 0.9), about
44 participants are needed. However, it is projected that
approximately 1,350 participants (out of 6780) will be
referred from the door-to-door visit. This number is de-
rived from a 20% prevalence of hypertension among
adults aged 35 years and older in the study area [27].
We estimate that roughly half of these 1,350 partici-
pants, being 675, will continue visiting the clinic for
treatment. Hence, this number of people is more than
sufficient for the analysis of our main primary outcome
at the clinic level.
Analysis
Due to the fact that the slums are part of a large demo-
graphic surveillance site and therefore not randomized,
we will use the double-difference method [40] to evaluate
the primary outcomes in the intervention versus control
sites. In this approach, Impact = (Yp(t>0) – Yp(t=0)) –
(Yc(t>0) – Yc(t=0)) where Yp is the primary outcome in
the intervention group and Yc is the outcome in the
control group. For the double-difference method to work,
it is essential that there are at least two pre-intervention
data points. In addition, having many preintervention data
points allows for the detection of shifts or interruptions in
trends (if any) after the introduction of an intervention. A
cross-sectional study conducted in the NUHDSS from
2008–2009 provides one time point of pre-intervention
data on CVD risk in the intervention and control slums
[27]. Note that cardiovascular risk reduction will be calcu-
lated by entering the outcomes in a non-laboratory-based
CVD risk assessment chart [33]. Regression analyses will
also be performed to investigate the association of each
risk factor with the main outcomes such as blood pres-
sure. Specifically, multivariate analyses will be used to ad-
just for known or perceived confounding variables while
comparing outcomes between intervention and control
sites. Prior to this, descriptive statistics will be applied to
compare characteristics of the intervention and control
sites. For behavioral risk factor analysis, we will use an in-
terpretive descriptive approach with matrix comparisons
between groups (such as sex, age group and site).
Cost-effectiveness analysis will be conducted according
to the WHO framework for cost-effectiveness analysis
[41]. This framework will consider intervention effect-
iveness data based on changes in blood pressure and
overall predicted cardiovascular risk at the population
level, as well as cost data on the intervention. The over-
all cost-effectiveness of the intervention package will be
calculated in terms of DALYs averted per US dollar.
Intervention cost will be estimated using a micro-
costing approach where feasible. Micro-costing is a
process of systematically identifying and measuring re-
source utilization using a process tracking system and
interviews with the local program team [42]. According
to the Panel on Cost-Effectiveness in Health and Medi-
cine, the theory and process of valuing costs through a
micro-costing methodology rest on a three-step approach:
identification, measurement and valuation of resources
used [43]. For other non-specific costs, gross costing
methods will be considered. Once resource utilization has
been measured, the component-specific costs of the inter-
vention can be computed by multiplying the quantity of
each type of resource consumed by unit costs. The
component-specific costs can be summed up to get the
total costs of the intervention [42]. Finally, the outcome of
this analysis will be the average cost for CVD risk reduc-
tion per participant per year. Data on costs and timings
will be collected from the preparation of the intervention
until the end of the intervention period. A yearly discount
rate of 3% will be used for long-term modeling and projec-
tions [44]. Estimations will be extended to project the
cost-effectiveness of the intervention package were it
implemented on a national scale.
Finally, in order to determine the scalability and feasibil-
ity of the intervention package, a comprehensive process
evaluation will be conducted involving analysis of oper-
ational data as well as qualitative sub-studies with benefi-
ciaries and other relevant stakeholders such as local policy
makers.
Additionally, since the package is to be implemented
in a private health sector setting, it will be important to
examine essential aspects of the intervention package
that are needed to translate the package to the public
sector.
Ethical approval
Ethical approval for this study was obtained from the
Kenyan Medical Research Institute (KEMRI), reference
KEMRI/RES/7/3/1 no. Non-SSC 399, dated 11 June 2012,
renewable annually. Informed consent will be applied to
all participants, and the overall study complies with the
Declaration of Helsinki principles.
Discussion
Although it is evident that a CVD epidemic is on the
rise in most countries in SSA [10], there is limited evi-
dence on the feasibility, cost-effectiveness and scalability
of comprehensive primary prevention programs for CVD
in these settings, in particular in the slum population.
There is a scarcity of studies in SSA on community-based
intervention for reduction of cardiovascular risk [30], and
very few of them have looked into the cost-effectiveness
[45] or scalability [46]. Considering the possibility of a
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double burden of disease that many countries in SSA are
facing, it is essential to provide insight into the health
impact and feasibility of primary prevention programs in
order to enable policymakers and other stakeholders to
make effective choices within their limited resources.
Despite the facts that the rise of CVD in SSA has been
strongly linked with urbanization, and a sizable majority
of the urban population in SSA is resident in slums,
there are no specific studies or programs designed for
this extremely vulnerable population. It is important to
share knowledge and experiences on how this growing
population at risk can be supported to reduce their car-
diovascular burden. Therefore, it is important to imple-
ment programs in these challenging living circumstances
and evaluate their feasibility and health effect. The
SCALE UP study is unique in this regard.
In our intervention package we focus specifically on
screening and treatment of hypertension as this is the
main modifiable risk factor to achieve CVD risk reduc-
tion in SSA [47]. It is our hope that the combination of
raised awareness through access to screening, improved
access to quality treatment and the promotion of adher-
ence will reduce hypertension rates in the study area to
the extent that it is significantly detectable at population
level. However, due to the depth of data that we will
collect as part of the study, we will also be able to assess
the effect of our intervention on behavioral risk factors
for CVD such as tobacco use, excessive alcohol intake,
poor dietary behavior and physical inactivity, as well as
biological CVD risk proxies such as body composition
(BMI) and blood glucose levels.
As mentioned previously, the content of our interven-
tion arose from a theoretical cost-effectiveness analysis.
Based on earlier studies done by APHRC and literature
review. we made estimations of the different interven-
tions possible in raising awareness, screening, treatment
and promoting adherence in a slum setting. The final
package is based on the theoretical effectiveness of each
individual intervention component. Should our analysis
prove the SCALE UP intervention be cost-effective, we
will then work with local stakeholders and policymakers
toward integrating the package in the larger health
sector. Additionally, this vision of the scalability of the
project not only implies the roll out of primary prevent-
ive services for CVD to more slums, but also provides
the opportunity for the integration of other essential
preventive services such as HIV testing or childhood
vaccinations. Therefore, we anticipate and hope that this
program will stimulate strengthening of weak health
systems and structures in the ever-expanding slum
settlements in SSA and beyond.
Our study is limited in the generalizability of the set-
ting where the intervention package is tested. The DSA
has been under surveillance for the past 10 years and
may not be typical of other slum settings where the
NUHDSS infrastructure does not exist. Another limita-
tion of our study is that the intervention package cannot
be evaluated in terms of its individual components. In
other words, it will be impossible to tease out which
parts of the intervention were most effective relative to
others. However, we are confident that the logical com-
position of the complete intervention package will make
it practical to implement as a whole in other similar
settings should the multi-component intervention have
an overall beneficial effect.
In conclusion, it is our hope that the outcomes of this
study will inform policy makers and health professionals
at various levels about the feasibility and cost-effectiveness
of implementing community-based cardiovascular risk
prevention programs in low- and middle-income coun-
tries, and specifically for the urban poor.
Trial status
Participant inclusion started in August 2012 and partici-
pant recruitment and follow-up at the intervention clinic
will continue until December 2013.
Additional file
Additional file 1: SCALE UP guidelines for management of
hypertension in primary care.
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